Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00864123 · ClinicalTrials.gov registry record · Phase 2
D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder
A Phase 2 study, sponsored by University of South Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00864123 is a Phase 2 study that has completed, run by University of South Florida. The registered enrollment target is 30 participants.
The verdict
NCT00864123, a Phase 2 study, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Cognitive-behavioral therapy (CBT) has proven efficacy for treatment of pediatric obsessive-compulsive disorder (OCD). Yet, CBT does not help all children and those who benefit often remain symptomatic upon treatment completion. Recent clinical trials in adults with other anxiety disorders (acrophobia and social phobia) provided support for using a medication called D-Cycloserine (DCS) to enahnce the outcome of exposure-based psychotherapy. Given this, DCS may augment CBT in youth with OCD, an anxiety disorder that is conceptually similar to acrophobia. With this in mind, the investigators are conducting a randomized, double-blind placebo controlled pilot study of DCS to determine whether it had any short-term clinical benefits on CBT in youth with OCD. Forty children and adolescents (ages 8-17) with a primary diagnosis of OCD will be screened and, should they meet relevant criteria, randomly assigned to one of two treatment conditions: (1) CBT plus DCS, or (2) CBT plus placebo. All patients will receive 10 sessions of CBT A rater will assess participants at 3 separate time points.
Interventions
- DRUG Placebo pill
- DRUG D-cycloserine
- BEHAVIORAL Cognitive-behavioral therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00864123
The ClinicalTrials.gov registry entry for NCT00864123 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo pill is the first listed.
NCT00864123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00864123 about?
NCT00864123 is a clinical study titled "D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder". Cognitive-behavioral therapy (CBT) has proven efficacy for treatment of pediatric obsessive-compulsive disorder (OCD). Yet, CBT does not help all children and those who benefit often remain symptomatic upon treatment completion. Recent clinical trials in adults with other anxiety disorders (acrophob...
What is the current status of trial NCT00864123?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2008-01. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00864123?
The interventions under investigation include: Placebo pill (DRUG), D-cycloserine (DRUG), Cognitive-behavioral therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00864123?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.